title: Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49.
abstract: We studied 18 consecutive patients with advanced colorectal cancer where primary tumors were preselected for high expression of TAG-72 antigen and who underwent a phase I radioimmunotherapy trial with an intravenously administered monoclonal antibody CC49, 20 mg, labeled with I-131 in amounts varying from 15 mCi/m2 to 75 mCi/m2. Whole-body images and SPECT of the abdomen obtained 1 week after infusion were compared with pretreatment CT scans. A total of 66 lesions were evaluated. SPECT revealed 2/66 lesions (3%) that were not detected by CT; 4/66 were only detected by CT: lungs (1.8 cm and < 1 cm), axilla (1.5 cm), adrenal (2.5 cm). Thus, based on immunohistopathological testing in paraffin-embedded tissue blocks of primary tumors stained for TAG-72 antigen, we have selected a subset of patients (about 70% of referrals) with colorectal cancer for whom I-131-CC49 was shown to target to 62/64 CT positive lesions (97%) and 62/66 (94%) of all known positive lesions. We conclude that in patients with significant TAG-72 tumor expression there is excellent targeting of I-131-CC49 in therapeutic doses to colorectal cancer with respect to lesions detected with CT scanning. It should be noted that this study was not designed as a comparison of the sensitivity of CT versus I-131-CC49 SPECT/planar imaging. Instead, the observed results are consistent with a biological hypothesis that in general, the primary tumor histology vis-à-vis TAG-72 expression reflects the TAG-72 expression of the metastatic sites.
authors.affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: L
authors.initials: L
authors.lastname: Kostakoglu
authors.forename: C R
authors.initials: CR
authors.lastname: Divgi
authors.forename: S
authors.initials: S
authors.lastname: Hilton
authors.forename: C
authors.initials: C
authors.lastname: Cordon-Cardo
authors.forename: A M
authors.initials: AM
authors.lastname: Scott
authors.forename: H
authors.initials: H
authors.lastname: Kalaigian
authors.forename: R D
authors.initials: RD
authors.lastname: Finn
authors.forename: J
authors.initials: J
authors.lastname: Schlom
authors.forename: S M
authors.initials: SM
authors.lastname: Larson
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000532:radiotherapy; D005260:Female; D006023:Glycoproteins / Q000032:analysis / Q000276:immunology*; D006801:Humans; D000922:Immunotoxins / Q000378:metabolism / Q000627:therapeutic use; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D006023:Glycoproteins; D000922:Immunotoxins; D007457:Iodine Radioisotopes; C047052:tumor-associated antigen 72